A $111 million Series A fundraising was concluded by Zephyr AI, Inc., a healthcare technology business situated in MCLean, VA, that is dedicated to creating explainable Artificial Intelligence (AI) solutions for precision medicine.
Among the backers were Revolution Growth, EPIQ Capital Group, Jeff Skoll, and Eli Lilly & Company.
The company plans to utilize the money to grow its scientific and commercial teams in order to accelerate the delivery of its pipeline of insights to the market, as well as to improve its analytical speed and strengthen its large collection of training and validation data sets.
Zephyr AI is creating better data federation tools and machine learning algorithms for cardiometabolic disease and oncology under the direction of co-founder and executive chairman Grant Verstandig and co-founder and interim CEO Jeff Sherman.
The company is building tools and products that help patients and clinicians and spur ongoing research by collecting a complete healthcare dataset through partnerships and proprietary data, then merging it with artificial intelligence algorithms to provide innovative, translatable insights.
Concerning Zephyr AI
A fast-growing healthcare technology startup, Zephyr AI is dedicated to completely changing precision medicine in cardiometabolic disease and oncology. Zephyr AI is assembling the most comprehensive healthcare dataset in the world through partnerships and proprietary data, combining it with state-of-the-art AI algorithms to produce new, interpretable insights that are used to develop tools and products that assist patients and providers and support ongoing research. Our goal-driven team of top software engineers and biologists at Zephyr AI uses big data and cutting-edge technology to create long-lasting relationships and transformative insights that will improve the way that cancer and cardiometabolic disease are treated.
